Made Scientific and Syenex Join Forces to Innovate T Cell Therapies
In an exciting development, Made Scientific, a prominent player in the cell therapy sector, has initiated a technology partnership with Syenex, a cutting-edge synthetic biology company. This collaboration aims to enhance the scalability and efficiency of engineered T cell therapies by utilizing Syenex's advanced bioengineering systems, UltraCell™ and RapidCell™. The partnership promises to offer significant improvements in gene delivery efficiency and streamline the engineering timelines that are crucial for effective treatments.
Technological Advancements in T Cell Therapy Manufacturing
This partnership builds upon the initial proof of concept achieved by leveraging Syenex’s bioengineering platforms. Together, Made Scientific and Syenex are addressing the critical scalability and cost challenges that plague traditional lentiviral- and retroviral-vector-based T cell therapy manufacturing processes. Notably, these innovative systems are reported to improve gene delivery efficiency by up to ten times significantly, while also reducing manufacturing timelines and costs through innovative delivery vector engineering.
Collaboration Study Outcomes
In their inaugural collaboration study, the two companies demonstrated that the RapidCell™ system serves as a viable alternative to conventional transduction and activation reagents. This new system not only streamlines workflows but does so in a more efficient and cost-effective manner. Initial results also indicate that RapidCell™ can specifically enable transduction and activation of non-enriched cell populations, which can further optimize the manufacturing process and reduce expenses.
Future Plans and Expectations
Results from the proof-of-concept studies conducted by Made Scientific and Syenex will be shared at a dedicated forum. There is an eagerness within the team to transition towards a customer-accessible manufacturing platform process that incorporates these groundbreaking technologies, expected to debut soon.
Statements from Leadership
Syed T. Husain, Chairman & CEO of Made Scientific, expressed enthusiasm about the collaboration, stating, "We look forward to working alongside Syenex to solve the pressing challenges within cell therapy manufacturing regarding scalability, costs, and efficiency. By integrating Syenex's advanced systems into our manufacturing framework, we aim to provide therapeutic developers with an efficient and cost-effective platform, helping bridge the gap from research and development to Good Manufacturing Practices (GMP). This effort is critical in making life-saving therapies more accessible to those in need."
Similarly, Jay Rosanelli, Co-Founder and CEO of Syenex, shared his excitement about the partnership, saying, "We are delighted to collaborate with Made Scientific and showcase the capabilities of our UltraCell™ and RapidCell™ systems. Together, we strive to eliminate the barriers of scalability and cost, ultimately accelerating the journey towards developing life-saving therapies."
Shared Vision for T Cell Therapy
Both Made Scientific and Syenex find themselves in a unique position to expedite the development of next-generation T cell therapies. This partnership not only looks to enhance manufacturing capabilities but also aims to ensure that critical treatments are available to patients rapidly, ultimately making a significant impact on healthcare outcomes.
About Made Scientific
Made Scientific stands as a leading contract development and manufacturing organization (CDMO) in the U.S. specializing in both autologous and allogeneic cell therapies for clinical and commercial purposes. With two state-of-the-art manufacturing facilities in the U.S., Made Scientific blends the agility of a specialist CDMO with the global reach and resources provided by GC Corporation of South Korea, an established entity in the pharmaceutical and biotechnology fields.
About Syenex
Syenex is revolutionizing the biotechnology landscape by creating an open-science platform that enables developers to precisely program cells at scale. Drawing on the principles of synthetic biology and a global network of CDMOs, Syenex provides versatile delivery platforms that streamline the journey from discovery to GMP manufacturing. Founded in 2022, the company has formed over 50 partnerships within the industries of biopharma and academia, resulting in a robust portfolio of delivery methods for both ex vivo and in vivo applications.
Frequently Asked Questions
What is the purpose of the Made Scientific and Syenex partnership?
The partnership aims to enhance the scalability and efficiency of engineered T cell therapies through innovative bioengineering systems.
What technologies are being utilized in the partnership?
Syenex's UltraCell™ and RapidCell™ bioengineering systems are key technologies that will be employed to improve gene delivery efficiencies.
How will the partnership impact T cell therapy costs?
By leveraging advanced delivery systems, the partnership aims to significantly lower the cost of goods and reduce manufacturing timelines.
What are the expected results of their initial studies?
Initial studies have shown that RapidCell™ may enhance the transduction and activation of various cell populations cost-effectively.
When can we expect to see results from this partnership?
Results from the collaborative studies will be presented at an upcoming forum, with a goal to launch a customer-accessible platform shortly thereafter.
